aldo-keto reductase family 7 like (gene/pseudogene)Genealiases: AFAR3 · AFB1-AR 3 · AFB1-AR3 · AKR7A4
Q-omics provides the consensus-scored AKR7L profile across patient tissues and cancer cell-line models. AKR7L expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, AKR7L is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, AKR7L RNA expression shows 17,308 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where AKR7L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKR7L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKR7L survival associations across molecular data types. AKR7L RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKR7L RNA expression–survival associations across cancer types. High AKR7L expression shows unfavorable associations in ACC and KICH, but favorable associations in KIRP, SKCM, BRCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for AKR7L RNA expression.
This table summarizes AKR7L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for AKR7L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKR7L shows lower tumor expression in KICH, THCA and KIRP and higher tumor expression in COAD, UCEC and BRCA. The KICH box plot shows higher AKR7L RNA expression in normal versus tumor tissue (log2 FC = −1.707, t-test p < 0.001).
This table shows molecular features associated with AKR7L in patient tissues and cancer cell lines. In patient samples, AKR7L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AKR7L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
